홈 › 다발성 골수종 › 앨라배마 › Birmingham
AL Birmingham의 다발성 골수종 임상 시험
다발성 골수종 관련 연구 18개가 Birmingham 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
피험자 모집 중1/2상
- University of Alabama At Birmingham Hospital, Birmingham
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
피험자 모집 중2상
- University of Alabama Birmingham, Birmingham
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
피험자 모집 중3상
- Alabama Oncology, Birmingham
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
피험자 모집 중1/2상
- University of Alabama at Birmingham Hospital, Birmingham
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
피험자 모집 중2상
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
피험자 모집 중3상
- University of Alabama at Birmingham, Birmingham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
피험자 모집 중2상
- University of Alabama at Birmingham, Birmingham
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
피험자 모집 중1/2상
- University of Alabama at Birmingham, Birmingham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
피험자 모집 중1/2상
- Research Site, Birmingham
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
피험자 모집 중1상
- University of Alabama at Birmingham, Birmingham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
피험자 모집 중2상
- University of Alabama at Birmingham, Birmingham
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
피험자 모집 중1상
- University of Alabama at Birmingham, Birmingham
Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
피험자 모집 중1상
- University of Alabama at Birmingham, Birmingham
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
피험자 모집 중2상
- University of Alabama at Birmingham, Birmingham
Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
피험자 모집 중
- Kirklin Clinic of UAB Hospital, Birmingham
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
피험자 모집 중관찰 연구
- Kirklin Clinic of UAB Hospital, Birmingham
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
피험자 모집 중1상
- University of Alabama at Birmingham, Birmingham
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
피험자 모집 중1/2상
- UAB Comprehensive Cancer Center, Birmingham
다른 도시의 다발성 골수종 시험
- New York City, NY연구 60개
- Boston, MA연구 42개
- Atlanta, GA연구 41개
- Houston, TX연구 38개
- Durham, NC연구 37개
- Nashville, TN연구 32개
- Denver, CO연구 26개
- Rochester, MN연구 24개
- Columbus, OH연구 24개
- Baldwin Park, CA연구 23개
- St. Louis, MO연구 23개
- Chicago, IL연구 22개
Birmingham의 다른 연구
- 암 (전체)연구 31개
- 유방암연구 24개
- 비만연구 23개
- 난소암연구 23개
- 비소세포폐암연구 22개
- 급성 골수성 백혈병연구 21개
- 심혈관 질환연구 17개
- 만성 폐쇄성 폐질환연구 17개
- 과체중연구 16개
- 낭성 섬유증연구 16개
- 자궁내막암연구 16개
- 제2형 당뇨병연구 16개
ClinicalTrials.gov 출처, 2026. 10. 1. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.